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DrOBJECTIVES The authors assessed the use of dual antiplatelet therapy (DAPT) and outcomes in patients undergoing
percutaneous coronary intervention (PCI) during the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
BACKGROUND The frequency, patterns, and outcomes when adding DAPT to non-vitamin K antagonist oral antico-
agulants in the setting of PCI in patients with AF are largely unknown.
METHODS The study population included all patients in the treatment group of the ROCKET AF trial divided by the
receipt of PCI during follow-up. Clinical characteristics, PCI frequency, and rates of DAPT were reported. Clinical out-
comes were adjudicated independently as part of the trial.
RESULTS Among 14,171 patients, 153 (1.1%) underwent PCI during a median 806 days of follow-up. Patients treated
with rivaroxaban were signiﬁcantly less likely to undergo PCI compared with warfarin-treated patients (61 vs. 92;
p ¼ 0.01). Study drug was continued during PCI in 81% of patients. Long-term DAPT ($30 days) was used in 37%
and single antiplatelet therapy in 34%. A small number switched from DAPT to monotherapy within 30 days of PCI
(n ¼ 19 [12.3%]) and 15% of patients received no antiplatelet therapy after PCI. Rates of stroke/systemic embolism and
major bleeding events were high in post-PCI patients (4.5/100 patient-years and 10.2/100 patient-years) in both
treatment groups.
CONCLUSIONS In patients with AF at moderate to high risk for stroke, PCI occurred in <1% per year. DAPT was used in
a variable manner, with the majority of patients remaining on study drug after PCI. Rates of both thrombotic and bleeding
events were high after PCI, highlighting the need for studies to determine the optimal antithrombotic therapy.
(J AmColl Cardiol Intv 2016;9:1694–702)© 2016 by the American College of Cardiology Foundation. Published by Elsevier.
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AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
DAPT = dual antiplatelet
therapy
DOAC = direct-acting oral
anticoagulants
MI = myocardial infarction
PCI = percutaneous coronary
intervention
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1695I n patients undergoing percutaneous coronaryintervention (PCI), the prevalence of atrial ﬁbril-lation (AF) is substantial and may be increasing
(1). An indication for oral anticoagulation, such as
AF, in patients who require antiplatelet therapy for
PCI can make therapeutic choices difﬁcult (2). Previ-
ous investigation has shown that the combination
of oral anticoagulation and antiplatelet therapy
increases the risk of bleeding (3–6). However, there
are few data on the combination of direct oral anti-
coagulants with dual antiplatelet therapy (DAPT) in
the post-PCI setting. In the Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared with
Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation (ROCKET
AF) (7), patients taking DAPT were excluded from
enrollment, but participants who underwent PCI
during the conduct of the trial were allowed to
continue study drug and the use of antiplatelet
therapy, as well as duration, was left to the investi-
gators’ discretion.SEE PAGE 1703To understand more about the combination of
rivaroxaban and antiplatelet therapy in the post-PCI
setting, we analyzed patients in the ROCKET AF
trial who underwent PCI during the study. We aimed
ﬁrst to describe the incidence of PCI and character-
istics of the population that required PCI during the
ROCKET AF trial. We then aimed to describe the
patterns of antiplatelet therapy in the post-PCI
setting, and ﬁnally the clinical outcomes of patients
undergoing PCI and on combinations of oral anti-
coagulation and antiplatelet therapy.
METHODS
STUDY POPULATION. The ROCKET AF trial design,
methods, and primary results have been pub-
lished (7,8). Brieﬂy, ROCKET AF was a randomized,
double-blind, double-dummy international non-
inferiority trial that compared ﬁxed-dose rivaroxaban
(20 mg/d or 15 mg/d in participants with a creatinineOrtho-McNeil-Janssen Pharmaceuticals, Pﬁzer, and Sanoﬁ-Aventis. Dr. Ha
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adjusted warfarin (maintaining an interna-
tional normalized ratio in the therapeutic
range [2.0–3.0]) for the prevention of stroke in
nonvalvular AF. Patients enrolled had to have
prior stroke or transient ischemic attack or
$2 risk factors for stroke. Patients with only 2
risk factors were capped at 10% of the overall
trial population. The primary endpoint was
stroke or non–central nervous system embo-
lism. For these analyses, we included all pa-
tients in the ROCKET AF trial who received $1 dose of
study drug; the intention-to-treat population was
used for efﬁcacy outcomes and the safety population
for bleeding outcomes.
OUTCOMES. The outcomes evaluated in our study
included the composite (and component events) of all
stroke and non–central nervous system (or systemic)
embolism, vascular death, and myocardial infarction
(MI). Stroke was deﬁned as a sudden, focal neurologic
deﬁcit resulting from a presumed cerebrovascular
cause that is not reversible within 24 hours and not
due to a readily identiﬁable cause, such as a tumor or
seizure. Non–central nervous system systemic em-
bolism was deﬁned as abrupt vascular insufﬁciency
associated with clinical or radiologic evidence of
arterial occlusion in the absence of other likely
mechanisms (e.g., trauma, atherosclerosis, or instru-
mentation). MI was deﬁned by clinical symptoms
consistent with MI and cardiac biomarker elevation
(troponin I or T, creatine kinase myocardial band)
greater than the upper limit of normal, the develop-
ment of new pathological Q waves in $2 contiguous
electrocardiography leads, or conﬁrmed by autopsy.
Vascular death was deﬁned as having been caused
by vascular events such as stroke, embolism, or
acute MI. The safety outcomes evaluated were Inter-
national Society on Thrombosis and Haemostasis
major bleeding, deﬁned as clinically overt bleeding
associated with any of the following: fatal outcome,
involving a critical site (i.e., intracranial, intraspinal,
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TABLE 1 Baseline Ch
Age, yrs
Female
BMI, kg/m2
SBP, mm Hg
DBP, mm Hg
Type of AF
Persistent
Paroxysmal
Newly diagnosed
Previous medication us
Aspirin
VKA
CHADS2 score
CHADS2 score
1
2
3
4
5
6
Coexisting condition
Prior stroke/TIA/non
embolism
Congestive HF
Hypertension
Diabetes
Prior MI
PAD
COPD
CrCl, ml/min*
Values are median (25th, 7
Cockcroft-Gault equation.
AF ¼ atrial ﬁbrillation; B
Years, Diabetes Mellitus [1
CNS ¼ central nervous sy
DBP ¼ diastolic blood pres
PCI ¼ percutaneous coron
transient ischemic attack; V
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1696with compartment syndrome, or retroperitoneal), or
clinically overt bleeding associated with a fall in
hemoglobin concentration of $2 g/dl or leading to
transfusion of $2 U of packed red blood cells or whole
blood, and clinically relevant nonmajor bleeding
deﬁned as overt bleeding not meeting the criteria
for major bleeding but associated with medical
intervention, unscheduled contact with a physician
(visit or telephone call), temporary (i.e., by delaying
the next study drug administration) cessation
of study drug, pain, or impairment of daily activ-
ities. All events in ROCKET AF were adjudicated
independently by a blinded, multispecialty adjudi-
cation committee.aracteristics
Overall
(N ¼ 14,171)
Patients
With PCI
(n ¼ 153)
Patients
Without PCI
(n ¼ 14,018) p Value
73 (65, 78) 73 (67, 79) 73 (65, 78) 0.305
5,605 (39.6) 27 (17.6) 5,578 (39.8) <0.001
28.2 (25.1, 32.0) 28.9 (26.0, 32.4) 28.2 (25.1, 32.0) 0.105
130 (120, 140) 130 (120, 140) 130 (120, 140) 0.039
80 (70, 85) 80 (70, 82) 80 (70, 85) 0.024
0.247
11,485 (81.1) 116 (75.8) 11,369 (81.1)
2,490 (17.6) 34 (22.2) 2,456 (17.5)
196 (1.4) 3 (2.0) 193 (1.4)
e
5,184 (36.6) 65 (42.5) 5,119 (36.5) 0.128
8,853 (62.3) 113 (73.9) 8,740 (62.3) 0.004
3.5  0.9 3.5  1.0 3.5  0.9 0.928
3 (0.0) 0 (0.0) 3 (0.0)
1,857 (13.1) 25 (16.3) 1,832 (13.1)
6,169 (43.5) 60 (39.2) 6,109 (43.6)
4,067 (28.7) 40 (26.1) 4,027 (28.7)
1,797 (12.7) 26 (17.0) 1,771 (12.6)
278 (2.0) 2 (1.3) 276 (2.0)
-CNS 7,767 (54.8) 86 (56.2) 7,681 (54.8) 0.726
8,851 (62.5) 82 (53.6) 8,769 (62.6) 0.023
12,824 (90.1) 132 (86.3) 12,692 (90.5) 0.074
5,647 (39.9) 75 (49.0) 5,572 (39.7) 0.020
2,446 (17.3) 50 (32.7) 2,396 (17.1) <.001
832 (5.9) 18 (11.8) 814 (5.8) 0.002
1,481 (10.5) 17 (11.1) 1,464 (10.4) 0.790
67 (52, 87) 71 (53, 88) 67 (52, 87) 0.483
5th percentile), n (%), or mean  SD. *Creatinine clearance was calculated using the
MI ¼ body mass index; CHADS2 ¼ Congestive Heart Failure, Hypertension, Age $75
point for presence of each], and Stroke/TIA [2 points]; scores range from 0 to 6;
stem; COPD ¼ chronic obstructive pulmonary disease; CrCl ¼ creatinine clearance;
sure; HF ¼ heart failure; MI ¼ myocardial infarction; PAD ¼ peripheral artery disease;
ary intervention; SBP ¼ systolic blood pressure; SD ¼ standard deviation; TIA ¼
KA ¼ vitamin K antagonist.STATISTICAL METHODS. Baseline characteristics,
including patient demographics, risk factors, medical
history, and baseline medications were calculated
with cohorts divided by PCI status and randomized
treatment group. Continuous variables are presented
as medians (25th, 75th percentiles) and categorical
variables are presented as counts (percentages).
Within the PCI study population, the time to ﬁrst PCI
was described in both treatment groups as well as
baseline characteristics of these patients, the patterns
of antiplatelet use with mean duration of use, and the
clinical outcomes stratiﬁed by treatment group and
analyzed as unadjusted event rate per 100 patient-
years. Type of procedure and stents placed were
also described. All statistical analyses of the aggre-
gate, de-identiﬁed data were performed by the Duke
Clinical Research Institute (Durham, North Carolina)
using SAS software (version 9.2, SAS Institute, Cary,
North Carolina).
RESULTS
There were 153 patients (1.1%) who underwent PCI in
ROCKET AF, 61 in the rivaroxaban treatment arm and
92 in the warfarin treatment arm during a median
806 days of follow-up. Median length of follow-up
was statistically similar between treatment groups
(841 days in rivaroxaban-treated patients vs. 791
days in warfarin-treated patients; p ¼ 0.29). Patients
undergoing PCI were similar in age, but less often
female, more likely to have been on prior vitamin K
antagonist agents, and more likely to have had a
prior MI or diabetes compared with patients who did
not undergo PCI (Table 1). They had similar stroke
risk, as measured by CHADS2 (Congestive Heart
Failure, Hypertension, Age $75 Years, Diabetes
Mellitus [1 point for presence of each], and Stroke/
TIA [2 points]; scores range from 0 to 6) scores, and
similar creatinine clearance. Among the PCI cohort,
the clinical characteristics of those receiving rivar-
oxaban were similar to those receiving warfarin
(Online Table 1).
FREQUENCY OF PCI AND PROCEDURAL CHARACTERISTICS.
There was a consistently small but increasing inci-
dence of PCI over time (Figure 1). Warfarin-treated
patients had a signiﬁcantly shorter time (273 vs. 370
days; p ¼ 0.011) to ﬁrst PCI compared with the
rivaroxaban-treated patients, and warfarin-treated
patients were more likely to undergo PCI during the
conduct of the trial. For procedural characteristics,
the use of bare metal stents was slightly higher than
the use of drug-eluting stents, and a minority of pa-
tients received balloon angioplasty alone (Table 2).
TABLE 2 Procedure Characteristics
All PCIs
(n ¼ 153)
Rivaroxaban
(n ¼ 61)
Warfarin
(n ¼ 92)
BMS 68 (44) 25 (41) 43 (47)
DES 53 (35) 21 (34) 32 (35)
Balloon angioplasty 25 (16) 14 (23) 11 (12)
Missing 7 (5) 1 (2) 6 (7)
Values are n (%).
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); other abbreviation as
in Table 1.
FIGURE 1 Time to First PCI Event for Patients on Rivaroxban Versus Warfarin
Warfarin-treated patients had signiﬁcantly shorter time to ﬁrst percutaneous cardiac
intervention (PCI) compared with rivaroxaban-treated patients.
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1697Across treatment groups, the use of stents/balloon
angioplasty was similar.
USE OF STUDY AND ANTIPLATELET THERAPY DURING
PCI. Patterns of antiplatelet therapy use after PCI
were variable; trial protocol recommended timing of
study drug cessation (Figure 2) but left study drug
resumption and antiplatelet medications to the in-
vestigators’ discretion. Nearly 81% of all patients
who underwent PCI remained on study drug
for $30 days after the procedure. After PCI, 37% of
patients received DAPT (clopidogrel and aspirin)
for $30 days, and approximately 34% of patients
were given monotherapy with clopidogrel or
aspirin. There was a small group of patients (15%)
who received study drug without antiplatelet ther-
apy, and a 12% rate of switching at approximately
30 days from DAPT to single antiplatelet therapy
(Figure 3).
OUTCOMES. In the 153 patients who underwent PCI,
rates of thrombotic and bleeding outcomes were
high. Rates of stroke or systemic embolism were 4.5
per 100 patient-years, whereas rates of major
bleeding were 10.5 per 100 patient-years. Comparing
patients with and without PCI, all ischemic and
thrombotic outcome event rates were higher in post-
PCI patients compared with patients who did not
undergo PCI (Table 3). Similar patterns were seen for
bleeding outcomes; patients with PCI were at sub-
stantially greater risk for bleeding events compared
with those who did not undergo PCI (Table 3). On
comparison of the treatment groups, there was a
numerically higher rate of stroke and vascular death
events in the warfarin group compared with the
rivaroxaban group (Table 4). The risk of the com-
posite outcome of stroke and systemic embolism was
similar between treatment groups as was the risk of
MI. For bleeding events, there was a numerically
increased rate of both major bleeding and the com-
posite of major and clinically relevant nonmajor
bleeding in those treated with rivaroxaban compared
with those treated with warfarin (Table 4). When
patients were divided by use of antiplatelet therapy
at 30 days after PCI, the rates of major bleeding were
high and similar across treatment groups for all pa-
tients (Online Table 2) and for those patients who
remained on study drug (81%) (Online Table 3).
When event frequency was plotted at follow-up time
intervals, there was a clustering of thrombotic and
bleeding events (Figure 4). Stroke, MI, systemic
embolic events, and major bleeding events predom-
inantly occurred within the ﬁrst 6 months after PCI.
Vascular deaths slowly accrued across the follow-up
time intervals.DISCUSSION
In a large, international cohort of patients with
nonvalvular AF at increased risk for ischemic stroke,
PCI was rare, occurring in only 1% of the patients
during follow-up. The majority of these patients
remained on anticoagulant study drug in the post-
PCI period, although the use of antiplatelet therapy
was variable. The rates of thrombotic and bleeding
outcomes were substantially elevated in patients
undergoing PCI and this risk persisted for 6 months
after the procedure. Although comparisons between
warfarin and rivaroxaban cannot be made with these
FIGURE 2 Periprocedural Strategy in ROCKET AF
Investigators were given discretion over how to manage study drug in the event of an invasive procedure, but were provided protocol guidance
in the setting of elective versus urgent versus emergent procedure for study drug management. For urgent and emergent procedures,
immediate cessation of study drug was necessary with monitoring and administration of therapeutic agents if the situation warranted.
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1698data, our results highlight the importance of caution
in these patients, and the need for further research
on the combination of non-vitamin K antagonist oral
anticoagulants (direct-acting oral anticoagulants
[DOACs]) and antiplatelet therapy in the setting
of PCI.FIGURE 3 Frequency of Concomitant Antiplatelet
Therapy Use
At 30 days after PCI in all patients undergoing PCI in ROCKET AF,
the majority of patients (80.5%) remained on study drug after
PCI therapy. Abbreviations as in Figures 1 and 2.RATE OF PCI IN ROCKET AF. Previous investigations
estimate that approximately 1% to 2% of adults have
AF and, over time, approximately 20% to 30% of
these adults will undergo PCI (9,10). Recently pub-
lished registry data indicate that rates of MI are
higher in patients with AF versus those without AF.
Soliman et al. (11) explored the Atherosclerosis Risk in
Communities (ARIC) database and found that rates of
MI were higher in patients with AF, particularly in
women and black patients. The unadjusted rates were
approximately 1% per year in patients with AF
compared with 0.5% per year in others. Soliman et al.
(12) found similar results in a post hoc analysis of the
REGARDS (REasons for Geographic and Racial Dif-
ferences in Stroke) study. Unadjusted rates of MI
were signiﬁcantly higher in patients with preexisting
AF (approximately 1% per year) than in those
without. When the population from the ROCKET
AF trial was examined, there were few patientsTABLE 3 Event Rates for Efﬁcacy and Safety Endpoints
Endpoint
Unadjusted Event Rate/100
Patient-Years (No. of Events)
No PCI (n ¼ 14,018) After PCI (n ¼ 153)
Stroke or systemic embolism 2.3 (568) 4.5 (7)
Stroke 2.1 (529) 3.1 (5)
MI 1.0 (253) 6.2 (7)
Vascular death 3.0 (763) 8.0 (13)
Major or NMCR bleeding 14.7 (2886) 31.7 (27)
Major bleeding 3.5 (766) 10.5 (12)
NMCR ¼ nonmajor clinically relevant; other abbreviation as in Table 1.
TABLE 4 Event Rates for Efﬁcacy and Safety Endpoints
According to Study Treatment Among PCI Patients
Endpoint
Unadjusted Event Rate/100
Patient-Years (No. of Events)
Rivaroxaban (n ¼ 61) Warfarin (n ¼ 92)
Stroke or systemic embolism 5.0 (3) 4.1 (4)
Stroke 1.6 (1) 4.1 (4)
MI 6.8 (3) 5.9 (4)
Vascular death 3.1 (2) 11.1 (11)
Major or NMCR bleeding 57.7 (15) 20.3 (12)
Major bleeding 15.0 (6) 8.1 (6)
Abbreviation as in Tables 1 and 3.
FIGURE 4 Proportion of Adverse Events After PCI
There is a clustering of events in the 6-month time window. Abbreviation as in Figure 1.
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1699(<1% per year) who underwent PCI during the median
2.5 year follow-up. Although this rate may seem low
compared with observational estimates, recent data
from large clinical trials provide context. In the
ARISTOTLE (Apixaban for the Prevention of Stroke
in Subjects With Atrial Fibrillation), ENGAGE AF-TIMI
48 (Effective Anticoagulation with Factor Xa Next
Generation in Atrial Fibrillation–Thrombolysis In
Myocardial Infarction 48) and RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy)
trials, rates of MI during follow-up were #1% per year
(13–15). Thus, the experience in the ROCKET AF trial
seems similar to other large international clinical trial
cohorts.
Despite the double-blind, double-dummy design
of the ROCKET AF trial, there was a signiﬁcant dif-
ference in rates of PCI between treatment arms. Pa-
tients treated with rivaroxaban were signiﬁcantly less
likely to undergo PCI compared with those on
warfarin. Potential explanations for this phenomenon
include the play of chance, a protective effect seen
with rivaroxaban above that seen with warfarin, or
“pseudo-unblinding.” There are 2 prospective ran-
domized clinical studies with rivaroxaban in the
prevention of acute coronary events. The ATLAS TIMI
46 (Rivaroxaban in Combination With Aspirin Alone
or With Aspirin and a Thienopyridine in Patients
With Acute Coronary Syndromes-Thrombolysis In
Myocardial Infarction 46) (16) and ATLAS 2 TIMI-51
(17) trials showed that in the post-ACS setting, rivar-
oxaban at low doses (5 and 2.5 mg) was effective in
reducing rates of cardiovascular death, stroke, and
MI, while also increasing rates of bleeding. However,
the patient population and concomitant medications
were very different in the ATLAS trials compared with
ROCKET AF, as were the dosing strategies. Thus, the
comparison may not be valid. Other factor Xa in-
hibitors have been tested in a similar manner (18),
without signals for substantial efﬁcacy in the sec-
ondary prevention of major adverse cardiovascularevents, but with increased risk for major bleeding
events. More detailed investigation on the effect of
rivaroxaban versus warfarin on further ischemic
events in patients with and without prior MI has been
published showing a nonsigniﬁcant 14% reduction in
the hazard (hazard ratio: 0.86; 95% conﬁdence in-
terval: 0.73 to 1.00; p ¼ 0.0509) for cardiovascular
death, MI, or unstable angina in patients assigned to
rivaroxaban compared with patients assigned to
warfarin (19). Pseudo-unblinding (in this context) is
the phenomenon by which investigators may have
obtained open laboratory values in the process of
clinical care (e.g., treatment for acute coronary syn-
drome) that would indicate the treatment group
assignment for their patient. This phenomenon may
have led to a differential practice pattern with respect
to performance of PCI. At the time of the ROCKET AF
trial, there were few data available on performance of
procedures like PCI while undergoing treatment with
a DOAC like rivaroxaban. Thus there may have been
hesitation to perform PCI in rivaroxaban-treated pa-
tients. Although this explanation is plausible, there is
no way to validate it.
Patients with an indication for chronic anti-
coagulation undergoing PCI still present a unique
challenge to health care providers. The optimal
medical therapy to reduce the risk of subsequent
Sherwood et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 6 , 2 0 1 6
Dual Antiplatelet Therapy and Outcomes in PCI A U G U S T 2 2 , 2 0 1 6 : 1 6 9 4 – 7 0 2
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bleeding is currently unknown. This lack was evident
in our population, with variable use of antiplatelet
therapy after PCI. This could also have been due to
the clinical trial setting, in which clinical providers in
the ROCKET AF trial may have been less comfortable
in the long-term prescription of antiplatelet therapy,
because the type of oral anticoagulation remained
blinded. Based on previous studies (20), the scope of
this problem remains large (>50,000 patients annu-
ally in the United States alone) and would seem to
only increase in the coming years, with the increasing
elderly population in Western countries, and the
more frequent use of DOACs. Our results highlight the
pressing need for further investigation of optimal
therapeutic combinations in these patients to under-
stand both pharmacodynamic as well as therapeutic
effects of these drugs.
TRIPLE THERAPY VERSUS ALTERNATIVES AND
COMBINATION OF DOAC WITH ANTIPLATELET
THERAPY. DAPT is effective in reducing stent
thrombosis and further adverse thrombotic events in
patients with acute coronary syndrome (21–23). Oral
anticoagulation is an effective therapy for reduction
of stroke risk in patients with AF at moderate to high
risk for stroke (7,14,24,25). Previous investigation
shows that any combination of oral anticoagulants
and antiplatelet therapy substantially increases the
risk of bleeding compared with either alone (2–4,6).
Much of the data are observational, but are
convincing given their consistent message. A current
European consensus statement suggests a risk-based
approach dependent on thrombotic risk (as esti-
mated by the CHA2DS2-VASc score) and clinical situ-
ation (stable coronary artery disease vs. acute
coronary syndrome) (26). There have been few ran-
domized clinical trials on this important question.
The WOEST (What is the Optimal antiplatelet and
anticoagulant therapy in patients with oral anti-
coagulation and coronary Stenting) trial was an
open-label, randomized clinical trial that examined
the use of oral anticoagulation (warfarin) and clopi-
dogrel with or without additional aspirin (9). The
WOEST trial of 573 patients randomized to warfarin
and clopidogrel, with or without concomitant aspirin,
demonstrated that additional aspirin was not associ-
ated with added thrombotic protection, but signiﬁ-
cantly increased bleeding risk (9). Data from the
WOEST trial are compelling, and have prompted re-
visions to the aforementioned European consensus
document. The ISAR-TRIPLE (Triple Therapy in
Patients on Oral Anticoagulation After Drug Eluting
Stent Implantation) study evaluated a differentstrategy for patients on oral anticoagulation under-
going PCI (27). In a randomized, open-label trial of 614
patients receiving concomitant aspirin and oral anti-
coagulation, subjects were randomized to receive
either 6 weeks of clopidogrel therapy or 6 months of
clopidogrel therapy. Over a follow-up of $9 months,
there was no difference in the primary endpoint
(composite of death, MI, stent thrombosis, or TIMI
major bleeding) between treatment arms. The authors
concluded that further studies evaluating the dura-
tion of potential therapy should be pursued. Despite
these encouraging ﬁndings, these results cannot be
extrapolated and applied to the use of DOACs with
clopidogrel or aspirin.
There are limited data available on the combina-
tion of aspirin or P2Y12 antagonists and DOACs. Dans
et al. (28) studied the combination of antiplatelet
agents with dabigatran versus warfarin in a second-
ary analysis of the RE-LY trial. They found that
concomitant antiplatelet therapy signiﬁcantly
increased rates of major and minor bleeding for pa-
tients on either dabigatran (150 and 110 mg) or
warfarin, but did not affect the beneﬁcial reduction
in stroke or systemic embolism seen with dabigatran.
In further analyses, DAPT further increased the risk
of major and minor bleeding compared with anti-
platelet monotherapy in combination with oral anti-
coagulation. Alexander et al. (29) showed similar
results in their secondary analysis of the ARISTOTLE
trial. Concomitant aspirin use was associated with an
increased risk of major and nonmajor clinically rele-
vant bleeding, but did not affect the beneﬁcial
reduction in thrombotic events seen with apixaban.
Our results also show an high risk for bleeding events
when combining antiplatelet therapy with oral
anticoagulation with either warfarin or rivaroxaban,
though the post hoc, nonrandomized, subgroup
analysis nature of our study limits further inter-
pretation. In addition, despite the frequent use of
concomitant antiplatelet therapy and anticoagul-
ation, the rates of thrombotic events were also high
in the post-PCI setting. These ﬁndings highlight the
challenges of treating patients with AF undergoing
PCI. These patients remain at very high risk for
bleeding events, but need potent therapies to address
their high thrombotic event risk (30,31). Although our
study population was small, limiting the depth of
analyses and comparisons that we could perform,
these data are among the very limited published
experience of patients with AF speciﬁcally undergo-
ing PCI on DOAC therapy.
FUTURE DIRECTIONS. These data continue to raise
questions about how to handle these new drugs,
PERSPECTIVES
WHAT IS KNOWN? In patients taking oral anticoagulation, the
addition of dual antiplatelet therapy signiﬁcantly increases
bleeding risk with little proven beneﬁt. Although the combina-
tion of vitamin K–based agents and P2Y12 inhibitors has been
studied, there is very little published on the combination of
direct-acting oral anticoagulants and dual antiplatelet therapy,
speciﬁcally in the setting of PCI.
WHAT IS NEW? We studied the antithrombotic therapy prac-
tice patterns and outcomes in patients undergoing PCI during the
ROCKET AF trial. In patients with AF at moderate-to-high risk for
stroke, PCI occurred in <1% per year. Dual antiplatelet therapy
was used in a variable manner, with the majority of patients
remaining on the study drug after PCI. Rates of both thrombotic
and bleeding events were high after PCI, highlighting the need
for studies to determine the optimal antithrombotic therapy for
patients requiring OAC who undergo PCI.
WHAT IS NEXT? Several ongoing studies are investigating the
optimal combination of DOACs and antiplatelet therapy.
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1701both in the setting of PCI, and in concert with anti-
platelet agents. Currently, the PIONEER AF-PCI
(A Study Exploring Two Strategies of Rivaroxaban
[JNJ39039039; BAY-59-7939] and One of Oral Vitamin
K Antagonist in Patients With Atrial Fibrillation Who
Undergo Percutaneous Coronary Intervention) trial
(NCT01830543) (32) has been initiated to evaluate
this speciﬁc question for rivaroxaban. Trials evalu-
ating the combination of antiplatelet drugs with
dabigatran and apixaban in the PCI setting have also
been initiated (33). There are several challenges to
investigators, such as the choice of drug-eluting
versus bare metal stents, the duration of potential
triple therapy, and the use of newer more potent
antiplatelet agents in patients at high risk for
bleeding. Although these are complex issues, trials
such as PIONEER AF-PCI, REDUAL PCI (Evaluation of
Dual Therapy With Dabigatran vs. Triple Therapy
With Warfarin in Patients With AF That Undergo a PCI
With Stenting), and AUGUSTUS (An Open-label, 2  2
Factorial, Randomized Controlled, Clinical Trial
to Evaluate the Safety of Apixaban vs. Vitamin K
Antagonist and Aspirin vs. Aspirin Placebo in Pa-
tients With Atrial Fibrillation and Acute Coronary
Syndrome or Percutaneous Coronary Intervention)
are necessary to determine the optimal medical
therapy for patients who require chronic oral anti-
coagulation and undergo PCI.
STUDY LIMITATIONS. First, it was a post hoc sub-
group analysis of the ROCKET AF trial and thus
is subject to selection bias, and both measured and
unmeasured confounding. There were few PCIs
and clinical events after PCI, which limits the power
and types of comparisons that could be made. The
timing of medications and urgency of indications
were not available for all PCIs, again limiting the an-
alyses we could perform. Indications for PCI were not
available for all patients, but of those patients (86
[56%]) with clearly referenced indications, 42 (49%)
had PCI for an indication of acute coronary syndrome,
20 (23%) were preplanned elective cases, and the
remainder had PCI for other adverse events (atypical
chest pain, etc.).CONCLUSIONS
In the ROCKET AF trial, a large international popu-
lation of patients with AF at increased risk for stroke,
PCI occurred infrequently, in 1.1% of patients during
follow-up. DAPT was used in a variable manner, but
the majority of patients remained on the study drug
after PCI. Rates of both thrombotic and bleeding
events were high in the post-PCI period and most
events occurred within 6 months. These results
highlight the need for caution in these patients and
should drive further research on the combination of
DOACs and antiplatelet therapy in the setting of PCI.
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